Glympse Bio raises more than $46M in Series B round for biosensor technology
The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for the disease.
Glympse Bio raises $22 million in Series A round for disease monitoring tech
ARCH Ventures and LS Polaris Innovation Fund led the round, which the company will use to develop the tech in diseases like NASH, its lead indication.
presented by
5 Major Trends Emerging in Healthcare Benefits in 2025
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.